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WHAT THIS PAPER ADDS
 Despite widespread use of endovascular therapy (EVT) for infrapopliteal lesions in patients with critical limb ischaemia (CLI),
morphological classiﬁcation of infrapopliteal lesions has not been updated since the TASC 2000 guideline to reﬂect revascular-
isation modality selection. Also, anatomical features of infrapopliteal lesions associated with major adverse limb events (MALEs)
remain unclear. We therefore sought to deﬁne a morphological classiﬁcation based on anatomical factors associated with MALE in
this setting. From this results, vessel diameter <2.5 mm, lesion calciﬁcation and below-the-ankle disease were associated with
MALE after infrapopliteal angioplasty. This risk stratiﬁcation based on these predictors allows us to estimate future incidence of
MALE in CLI patients involving pure isolated infrapopliteal lesions.a r t i c l e i n f o
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Objective: To identify anatomical factors associated with major adverse limb events (MALE) after
angioplasty as the basis for a novel morphology-driven classiﬁcation of infrapopliteal lesions.
Design: Retrospective-multicenter study.
Materials and methods: Between March 2004 and October 2010, 1057 limbs from 884 patients with CLI
due to isolated infrapopliteal lesions were studied. Freedom-from MALE, deﬁned as major amputation or
any reintervention, was assessed out to 2 years by the KaplaneMeier methods. Anatomical predictors
and risk stratiﬁcation for MALE were analyzed by multivariate analysis.
Results: Freedom-from MALE was 47  1% at 2 years. Lesion calciﬁcation, target vessel diameter<3.0 mm,
lesion length>300 mm and no below-the-ankle (BA) run-off were positively associated with MALE by
multivariate-analysis. The total number of risk factors was used to calculate the risk score for each limbs
for subsequent categorization into 3 groups with 0 or 1 (low-risk), 2 (moderate-risk) and 3 or 4 (high-
risk) factors. Freedom-from MALE at 2 year-rates was 59% in low-risk, 46% in moderate-risk, and 29% in
high-risk, respectively.
Conclusion: Target vessel diameter <3.0 mm, lesion calciﬁcation, lesion length > 300 mm and no-BA run-
off were associated with MALE after infrapopliteal angioplasty. Risk stratiﬁcation based on these
predictors allows estimation of future incidence of MALE in CLI with isolated infrapopliteal lesions.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
fax: þ81 6 6419 1870.
E-mail address: iida.osa@gmail.com (Ociety for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Revascularisation of infrapopliteal lesions is indicated only for
patients with critical limb ischaemia (CLI),1,2 and The Inter-Society
developed in accordance with the Declaration of Helsinki, and
approved by the ethics committee of each hospital. This studyO. Iida et al. / European Journal of Vascular and Endovascular Surgery 44 (2012) 318e324 319Consensus for Management of PAD (TASC) classiﬁcation guides
choice of revascularisation strategy. Patients with CLI, especially
those with diabetes mellitus (DM) and end-stage renal disease
(ESRD) on dialysis, generally have long, calciﬁed, diffuse arterio-
sclerotic lesions in the infrapopliteal region;3,4 this morphology is
still considered best treated with saphenous vein graft bypass
surgery as ﬁrst-line therapy.2 For instance, the commonly
encountered occlusions longer than 2 cm or diffuse disease in the
tibial and peroneal arteries are deﬁned as TASC D which indicates
for bypass surgery (BSX) according to the TASC guideline,1 and few
patients with CLI therefore are clinically indicated for angioplasty
based on anatomical morphology. However, endovascular therapy
(EVT) with traditional angioplasty currently is most widely used in
the infrapopliteal region because it achieves technical and clinical
success rate of up to 90% and 70%, respectively, and acceptable and
in some cases slightly higher rates of limb salvage and amputation-
free survival (AFS) when compared to BSX.5,6 Moreover, patients
are commonly not suitable surgical candidates secondary to
comorbidities and advanced age.2
Based on the aforementioned considerations, the TASC-based
morphological classiﬁcation of infrapopliteal lesions does not
determine revascularisation modality selection in current clinical
practice. In revascularisation for coronary artery disease (CAD), on
the other hand, the SYNTAX score which is based on anatomical
features is used to predict future occurrence of major adverse
cardiac events (MACEs) and to decide indication for coronary artery
bypass graft (CABG) or percutaneous coronary intervention (PCI)
with drug-eluting stents (DESs).7,8 We therefore sought to deﬁne
anatomical predictors of major adverse limb event (MALE) in
patients with CLI due to pure isolated infrapopliteal lesions treated
with EVT.Methods
Enrollment
We retrospectively analysed our prospectively maintained
database, including data on 2519 limbs in 2141 consecutive CLI
patients,whounderwent EVT fromApril 2004 to June 2011 andwho
consented to a follow-up at each of the participating 11 cardiovas-
cular and vascular centres. To classify the severity of infrapopliteal
lesions, this study included patients with CLI due to pure isolated
infrapoliteal lesion who underwent EVT, and the infrapopliteal
anatomical predictors of MALEs in these patients were identiﬁed
and stratiﬁed as the basis for a novel anatomical classiﬁcation. We
excluded patients with involved suprapopliteal revascularisation.
During this period, patients with CLI due to infrapopliteal lesions
combined with either femoropopliteal (FP) lesions (47%, 1198 limbs
in 1025 patients) or aorto-iliac (AI)-FP lesions (10%, 263 limbs in 232
patients) were excluded from this study.We also excluded from this
analysis 170 patients considered to be poor candidates for both
forms of revascularisation due to severe comorbidities as well as
those who refused revascularisation, or who presented with acute
limb ischaemia requiring emergent revascularisation or function-
ally unsalvageable limbs. Finally, 1058 limbs from 884 consecutive
CLI patients suffering from intractable rest pain due to ischaemia
(Rutherford 4), or life-threatening non-healing ulceration/gangrene
(Rutherford 5 or 6) due to isolated infrapopliteal lesions were
included. A total of 44% of limbs (n ¼ 465) with isolated infrapo-
pliteal lesions overlapped with those included in a previous study.6
During the study period, 375 CLI patients were treated with crural
bypass therapy by a vascular surgeon. The study protocol waswas registered in the University Hospital Medical Information
Network Clinical Trial Registry (UMIN-CTR), whichwas approved by
the International Committee of Medical Journal Editors (no.
UMIN000007016, J-BEAT II registry: Japanese BElow-the-knee
Artery Treatment registry II). All patients gave written informed
consent prior to revascularisation.
Protocols
Our study protocol was reported previously.6 Brieﬂy, each arte-
rial pulsation was evaluated and tissue loss was recorded as part of
the preoperative vascular assessment. Lower limb severity was
haemodynamically assessed by the ankle-brachial index (ABI) and
skin perfusion pressure (SPP). Lower limb arteries were routinely
evaluated by duplex ultrasound and digital subtraction angiography
(DSA) before revascularisation. A group of vascular specialists
including vascular surgeons judged whether EVT was indicated for
each patient. All endovascular procedures were conducted under
local anaesthesia by a cardiologist, radiologist or vascular surgeon
depending on the institute. EVT was indicated when the lesion
showed >50% diameter stenosis on duplex ultrasound and/or
diagnostic angiography and haemodynamically underlying symp-
toms. Selection of EVTapproachwas left to the operator’s discretion.
An antegrade approach with a 3 or 4 Fr sheath from the ipsilateral
common femoral artery was commonly selected. After inserting the
sheath, unfractionated heparin (5000 U)was routinely injected into
the artery. A 0.014-inch guide wire was advanced into the culprit
lesion and an optimally sized balloon catheter was introduced. An
appropriate balloon diameter was chosen to match that of the non-
diseased artery adjacent to the lesion. Vessel diameter and lesion
length were visually assessed using preprocedural duplex and the
balloon catheter as reference. Decision of target lesionwas based on
lesion and limb severity. Target lesion was decided by the angio-
some concept in patients with tissue loss, and easily treatable
lesions were commonly selected in patients with rest pain. Dual
antiplatelet therapy was started at least 1 week prior to EVT and
continued lifelong. Antibiotics were routinely administered if the
ulcer was complicated with limb threatening severe infection; in
this case, the ulcer also was evaluated and managed by a plastic
surgeon using the TIME concept.
Deﬁnitions
The deﬁnition of lower limb severity and the diagnosis of
atherosclerosis risk factors has been reported previously.6 Critical
ischaemic limb was deﬁned in accordance with TASC as tissue loss
associated with an ankle pressure <70 mmHg or a toe pressure
<50 mm and rest pain associated with an ankle pressure
<50 mmHg or a toe pressure <30 mm. When these measurements
could not be obtained due to intractable rest pain or a non-
compressible artery secondary to severe calciﬁcation, the SPP was
measured; an SPP less than 40 mmHg was deﬁned as indicating
a critical ischaemic limb. CAD and cerebrovascular disease (CVD)
were deﬁned as the presence of symptom or past history of
infarction or history of any revascularisation. Lesion calciﬁcation
was deﬁned byangiographyas readily visible densities notedwithin
the apparent vascular wall. Below-the-ankle (BA) disease was
deﬁned as greater than 50% stenosis systemically affecting wound
healing and indicated for revascularisation at both of BA arteries.
When more than one vessel was treated by angioplasty, target
lesion in this analysis was decided based on the perfusion area by
ﬁnal angiogram. Treated lesion was chosen as the lesion affecting
the widest perfusion area in the limb. Procedural success was
Table 2
Baseline lesion characteristics before below-the-knee angioplasty.
Variables Overall, n ¼ 1057
TASC 2000 classiﬁcation (A/B/C), (%) 3%/1%/7%
TASC 2000 D 89% (945)
Lesion calciﬁcation 65% (682)
Target lesion length (mm) 190  96
Lesion length >100 mm 81% (855)
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region. Reintervention including repeat angioplasty or bypass graft
procedures were indicated for limbs with recurrent symptoms
accompanied by recurrent stenosis greater than 50% asmeasured by
duplex ultrasound or DSA. MALE was deﬁned as major amputation
or any reintervention, including surgical reconstruction or repeat
angioplasty. Major amputation was deﬁned as surgical excision of
the limb above the ankle. Any amputation at or distal to the Lisfranc
level was not considered a limb salvage failure. Amputation data
were obtained through outpatient clinic follow-up contact.
Study outcomes
Study outcome was freedom from MALE at 2 years; this
outcome is in accordance with the objective performance goals for
evaluating catheter-based therapies in CLI recommended by the
Society of Vascular Surgery (SVS).9 Also, anatomical-independent
predictors and risk stratiﬁcation for MALE were analysed. Risk
stratiﬁcation of AFS was also evaluated based on anatomical factor
of MALE.
Statistical analysis
Statistical analysis was performed using Statistical Package for
Social Sciences (SPSS) (SPSS Inc., Chicago, IL, USA). Data are shown
as mean  standard deviation or error. An unpaired t-test was used
to compare continuous variables between groups, and a chi-square
test was used to compare proportions between groups; the statis-
tical signiﬁcance level was set at p < 0.05. Independent outcome
determinants were identiﬁed by Cox proportional hazard ratio (HR)
in multivariable analysis including all variables from univariable
analysis with a p value of <0.1. We conducted risk stratiﬁcation
analysis for MALE and AFS using a simple score based on the
number of variables independently associated with MALE in
multivariable analysis. Freedom fromMALE and AFS rate according
to risk factor was estimated using the KaplaneMeier method and
compared using the log-rank test.
Results
Baseline patient and limb characteristics before angioplasty
Table 1 shows baseline patient and limb characteristics. Notable
baseline characteristics included patient age (71  10 years), DMTable 1
Baseline patient and limb characteristics.
Variables
Patients status
Age 71  10
Male 69% (612)
BMI (body mass index) 22  3
Risk factors
Hypertension 73% (647)
Hyperlipidemia 31% (276)
Diabetes mellitus 71% (627)
Current smoking 36% (318)
End stage renal disease on dialysis 62% (546)
Cardiovascular disease
CAD (Coronary Artery Disease) 51% (454)
CVD (Cerebrovascular disease) 24% (216)
COPD (Chronic obstructive pulmonary disease) 8% (68)
Limb status
Rutherford classiﬁcation 4.9  0.7
Tissue loss 74% (781)
ABPI before angioplasty 0.81  0.25(71%, 627/884) and ESRD on dialysis (62%, 546/884). Regarding limb
status, 74% (781/1057) of limbs were complicated with tissue loss.
Mean follow-up time was 18  15 months and death was occurred
in 31% (277/884) of patients.
Baseline lesion characteristics before angioplasty
Baseline lesion characteristics are shown in Table 2. A total of
3486 infrapopliteal lesions in 1058 limbs were analysed. Average
target lesion length was 190  96 mm and reference vessel diam-
eter (RVD) was 2.5  0.5 mm. Presence of TASC D lesion was
observed in 89% of cases. Calciﬁcationwas present in 65% of lesions.
RVD of peroneal arterywas smaller than that of other tibial arteries.
BA lesions were located in the dorsalis pedis and plantar arteries in
approximately 40% of cases. In this study, procedural success was
obtained in 96% (1010/1058) of the limbs.
Overall MALE
Two-year freedom fromMALE rate is shown in Fig. 1; it was 57%
and 47% at 1and 2 years, respectively.
Univariable and multivariable analysis for MALE
Comparison of lesion characteristics before angioplasty in
MALE (þ) and MALE () groups is shown in Table 3. There were
no signiﬁcant differences in baseline lesion characteristics
including TASC classiﬁcation and number of BTK run-off. RVD of
target lesion was smaller and lesion length was longer in the
MALE (þ) than in the MALE () group. Lesion calciﬁcation and
no-BA run-off, which was deﬁned as presence of lesion at both
of dorsalis pedis and plantar artery, were more frequently
observed in the MALE (þ) group. During the study phase, MALE
was observed in 43% (455/1058) of limbs. After multivariable
Cox proportional hazard regression analysis of MALE, lesion
calciﬁcation (HR, 1.38; 95% conﬁdence interval (CI),Target lesion % diameter stenosis before angioplasty 98  5
Below-the-knee Chronic total occlusion 62% (651)
Below-the-ankle Chronic total occlusion 62% (659)
Target lesion reference vessel diameter (mm) 2.5  0.5
Anterior tibial artery (ATA)
Vessel diameter (mm) 2.5  0.4
Intact/diseased 8% (85)/92% (972)
Occlusion 70% (737)
Posterior tibial artery
Vessel diameter (mm) 2.4  0.4
Intact/diseased 9% (98)/91% (959)
Occlusion 72% (760)
Peroneal artery
Vessel diameter (mm) 2.2  0.4
Intact/diseased 32% (340)/68% (717)
Occlusion 43% (457)
Number of below the knee run-offs 0.50  0.68
Three-vessel disease 60% (634)
Dorsalis pedis artery
Intact/diseased 62% (659)/38% (398)
Plantar artery
Intact/diseased 58% (617)/42% (440)
Presence of below-the-ankle disease 59% (627)
Number of below-the-ankle (BA) run-offs 1.2  0.8
Figure 1. Freedom from major adverse limb events (MALE) for 1057critical ischemic
limbs due to pure isolated infrapopliteal lesions after angioplasty. Overall freedom
from MALE was 57 and 47% at 1 and 2 years, respectively.
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<3 mm (HR, 1.26; 95% CI, 1.01e1.58, p < 0.05), lesion length
300 mm (HR, 1.47; 95% CI, 1.18e1.82, p < 0.05) and no-BA
run-off (HR, 1.75; 95% CI, 1.36e2.25, p < 0.01) were positively
associated with MALE.MALE according to each predictor
Fig. 2(aed) describe freedom from MALE for each predictor
according to multivariable logistic analysis. Freedom from MALE
rate in the target lesion in vessels with RVD <3 mm, target lesions
length 300 mm, lesions with calciﬁcation and no-BA run-off was
lower than in those with RVD 3 mm, target lesions length
<300 mm, lesions without calciﬁcation and without no-BA run-off.Risk stratiﬁcation for MALE
Fig. 3 shows stratiﬁcation of MALE by number of risk factors
after multivariable logistic analysis. The total number of risk factorsTable 3
Uni and multivariable analysis for MALE.
Lesion characteristics Unadjusted HR
[95% CI]
Adjusted HR
[95% CI]
TASC 2000 class D 1.16 [0.84, 1.60] 1.03 [0.71, 1.50]
Lesion calciﬁcation 1.42 [1.16, 1.73]** 1.38 [1.12, 1.69]**
Target lesion length 300 mm 1.47 [1.20, 1.81]** 1.47 [1.18, 1.82]**
Chronic total occlusion in BTK 1.28 [1.04, 1.58]* 1.22 [0.98, 1.53]
Lesion reference diameter <3 mm 1.37 [1.10, 1.71]** 1.26 [1.01, 1.58]*
Number of BTK run-offs
(vs. 3 run-offs)
1.00 (Ref) 1.00 (Ref)
2 run-offs 0.94 [0.58, 1.53] 0.85 [0.52, 1.39]
1 run-off 0.90 [0.58, 1.40] 0.71 [0.45, 1.15]
No run-off 0.95 [0.62, 1.46] 0.65 [0.41, 1.05]
Number of BA run-offs
(vs. 2 run-offs)
1.00 (Ref) 1.00 (Ref)
1 run-off 1.04 [0.84, 1.29] 1.15 [0.92, 1.44]
No run-off 1.62 [1.23, 2.05]** 1.75 [1.36, 2.25]**
Diseased calcaneal branch 0.98 [0.81, 1.18] 0.98 [0.80, 1.19]
*p < 0.05, **p < 0.01.
TASC: Trans-Atlantic Inter-Society Consensus.
BTK: below the knee, BA: below the ankle.was then used to calculate the risk score for each patient for
subsequent categorisation into three groups with zero or one (low-
risk), two (moderate-risk) and three or four (high-risk) risk factors;
patients were followed for up to 2 years. Freedom from MALE was
signiﬁcantly lower in higher-risk groups (2-year rates: low-risk,
59%; intermediate-risk, 46% and high-risk, 29%, respectively; low
vs. moderate: p ¼ 0.0003, low vs. high: p < 0.0001, moderate vs.
high: p < 0.0001).
Risk stratiﬁcation for AFS based on number of risk factors of MALE
Fig. 4 shows AFS rate according to number or risk factors of
MALE. AFS rate was signiﬁcantly lower in the higher-risk groups (2-
year rates: low-risk, 72%; moderate-risk, 62% and high-risk, 54%,
respectively; low vs. moderate: p¼ 0.0012, low vs. high: p< 0.0001,
moderate vs. high: p ¼ 0.0076).
Discussion
This multicentre study documents a 2-year freedom fromMALE
rate after infrapopliteal angioplasty was 47% and traditional TASC
classiﬁcation of infrapopliteal lesion not being associated with
future occurrence of MALE. Lesion calciﬁcation, RVD<3 mm, lesion
length 300 mm and no-BA run-off were independent anatomical
predictors for future occurrence of MALE after multivariable anal-
ysis. After adjusting the hazards ratio after multivariable analysis
based on risk score, freedom from MALE and AFS was lower in the
higher score groups. These results indicate that risk stratiﬁcation
based on anatomical factors might be useful in clinical practice to
estimate future occurrence of MALE and AFS.
Revascularisation outcomes commonly depend on anatomical
features and those affecting patency include lesion severity in run-
off arteries, stenosis/occlusion length and number of lesions
treated.1,2 While ilio-femoral TASC classiﬁcation schemes have
been modiﬁed from the original TASC 2000 guidelines to reﬂect
inevitable technological advances, infrapopliteal classiﬁcation has
remained unchanged. However, approaches for the treatment of
infrapopliteal arteries also have rapidly evolved yielding outcomes
comparable to those of BSX.10,11 The only trial attempting to
compare BSX and EVT for limb salvage is BASIL (bypass vs. angio-
plasty in treatment of severe leg ischaemia) trial. In this trial, which
examined CLI patients with infrainguinal arterial occlusive disease,
similar results at 2 years but better AFS rates for BSX thereafter
were observed; the choice of revascularisation technique (BSX or
EVT) was consequently proposed based on the presence of useable
vein and life expectancy.12,13 However, no angiographic data were
mentioned in the BASIL trial, and both FP and infrapopliteal lesions
were included. Furthermore, the BASIL trial had low external val-
idity, as only 6.8% of the patients undergoing infrapopliteal angio-
plasty were included. Recently, from the ESC guidelines on the
diagnosis and treatment of peripheral artery diseases, primary
percutaneous transluminal angioplasty (PTA) for infrapopliteal
arterial lesions remains the standard of care, as it provides an
acceptable clinical outcome at a low procedural cost compared to
BSX; these guidelines recommended that with class IIa level an
endovascular-ﬁrst strategy should be considered when revascu-
larisation in the infrapopliteal segment is indicated.14 Also, a new
recommendation published in the European Journal of Vascular and
Endovascular Surgery, angioplasty as the ﬁrst-line therapeutic
modality for patients with CLI and infrapopliteal lesion is reason-
able in the majority of cases, considering that the interventional
procedure should not preclude future surgical intervention.15
Despite the widespread use of primary PTA for the treatment of
CLI with infrapopliteal lesions, morphological classiﬁcation of
infrapopliteal lesions in the TASC guideline has not been updated to
Figure 2. a Comparison of freedom from MALE between target lesions with reference vessel diameter (RVD) < 3 mm and >¼ 3 mm Freedom from MALE rate in target lesions with
RVD < 3 mm was lower than in those with RVD >¼ 3 mm (46% vs. 54% at 24 months, p ¼ 0.0036). b Comparison of freedom from MALE between target lesions with length >¼
300 mm and <300 mm Freedom fromMALE rate in target lesions length >¼ 300 mmwas lower than in those with <300 mm (37% vs. 50% at 24 months, p ¼ 0.0002). c Comparison
of freedom from MALE in lesions with and without calciﬁcation Freedom form MALE was lower in lesions with calciﬁcation than in lesion without calciﬁcation (42% vs. 56% at 24
months, p ¼ 0.0005). d Comparison of freedom from MALE with and without below-the-ankle disease Freedom form MALE was lower in lesion with no-BA run-off than in lesion
without no-BA run-off (37% vs. 49% at 36 months, p < 0.0001).
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address this limitation, we investigated anatomical predictors of
MALE after infrapopliteal angioplasty for patients with CLI due to
pure isolated infrapopliteal lesions. To the best of our knowledge,
this is the ﬁrst attempt to identify novel anatomical predictors and
to use them for risk stratiﬁcation for future occurrence of MALE
following angioplasty in patients with CLI due to isolated infrapo-
pliteal lesions. Similar to the case with the ilio-femoral region, CLI
patients, especially those with DM and ESRD on dialysis, commonly
present with long, diffuse arteriosclerotic disease in the infrapo-
pliteal region; lesion length consequently was an anatomical
predictor for MALE. Comparison by KaplaneMeier analysis showeda lower rate of freedom from MALE in lesions with RVD <3 mm
compared to those with RVD 3 mm. This association of smaller
RVDwith worse outcomes after catheterisation treatment has been
seen in other arterial lesions including coronary, renal, iliac and the
other arteries.16e18 Lesion calciﬁcation also negatively affected
MALE after infrapopliteal angioplasty. Several prior studies have
identiﬁed lesion calciﬁcation as an important determinant for
coronary restenosis after both angioplasty and stent implanta-
tion.19,20 Lesion calciﬁcation provokes insufﬁcient balloon dilation
and loss of acute gain due to elastic recoil after angioplasty which
results in a high incidence of restenosis. Also, insufﬁcient initial
success in the presence of lesion calciﬁcation leads to poorer
Figure 3. Risk stratiﬁcation for MALE based on number of risk factors after multi-
variable logistic analysis Freedom from MALE rate was lower in the higher risk groups
(2-year rates: low risk, 59%; moderate-risk, 46%; and high-risk, 29%, respectively; low
vs. moderate: P ¼ 0.0003, low vs. high: P < 0.0001, moderate vs. high: P < 0.0001).
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resulting in a greater likelihood of major amputation. Therefore, to
address this challenge, lesion preparation would be helpful to
modify the calciﬁed lesions and consequently lead to a better rate
of MALE. BA disease was also an independent predictor of MALE
after multivariable analysis. Factors negatively affecting patency inFigure 4. Risk stratiﬁcation for AFS (amputation-free survival) based on number of risk
factors of MALE AFS rate was lower in the higher risk groups (2-year rates: low risk,
72%; moderate-risk, 62%; and high-risk, 54%, respectively; low vs. moderate:
P ¼ 0.0012, low vs. high: P < 0.0001, moderate vs. high: P ¼ 0.0076).AI and FP revascularisation include quality of BTK run-off vessels in
TASC II.2 Therefore, incidence of no-BA run-off as outﬂow vessel of
BTK run-off accordingly plays an important role in affecting not
only future occurrence of reintervention and surgical conversion
but also incidence of major amputation after infrapopliteal angio-
plasty. Technique improvement and the availability of dedicated
materials have resulted in improved clinical outcomes after endo-
vascular treatment of patients with CLI due to isolated infrapopli-
teal lesions. However, classiﬁcation of the infrapopliteal region has
not yet been systematically updated and reconsidered in patients
with CLI due to isolated infrapopliteal artery lesions. The results of
this study should help inform selection of revascularisation
strategy for patients with CLI due to isolated infrapopliteal lesions
and this novel classiﬁcation will be an attractive alternative to
traditional infrapopliteal TASC classiﬁcation.
Limitations
This was a retrospective and non-randomised study despite use
of a prospectively maintained database with a very large number of
CLI patients with isolated infrapopliteal lesions. Lack of complete
follow-up to 2 years for all patients was presented in this study
because of retrospective investigation. Patients considered unsuit-
able for revascularisation or treated with bypass therapy were not
managed by the physicians involved in the study; therefore, data on
these patients were not collected and analysed. Also, lesion char-
acteristics before bypass therapy were not included in this study.
Device use was limited to traditional balloon angioplasty, which
was the only option available in Japan at the time of this study.
However, infrapopliteal angioplasty has been widely used for
treatment of CLI patients as is the case in our clinical practice. Newer
classiﬁcation in the era of next-generation devices for BTK inter-
vention warrants further investigation against bypass results.
Conclusion
RVD, lesion length, calciﬁcation and no-BA run-off were asso-
ciatedwithMALE after infrapopliteal angioplasty. Risk stratiﬁcation
based on these predictors plays an important role in estimating
future incidence of MALE and AFS in CLI patients involving infra-
popliteal lesions.
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